Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)

Three clinical trials centers now open for enrollment; two additional ones initiating

LOS ALTOS, Calif., January 9, 2020 -- Retrotope announced today that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of the inherited ataxias. RT001, a stabilized fatty acid drug, has been shown to reduce lipid peroxidation leading to cell death in patients across a wide swath of degenerative diseases, including FA. More information and a list of participating clinical sites for the current trial in FA can be obtained at ClinicalTrials.gov http://bit.ly/2T2FWA5. With this trial, the company expands its pipeline of indications for RT001 which is currently being studied in a pivotal trial in another fatal, neurodegenerative disease, Infantile Neuroaxonal Dystrophy (INAD), which is fully enrolled.

View the entire Press Release HERE

SHARE

FacebookTwitterLinkedInYoutube
Science C.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News


Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator